logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

DMALL (02586) spent 3.138 million Hong Kong dollars on January 30 to repurchase 374,500 shares.

date
20:46 30/01/2026
avatar
GMT Eight
Deloitte China (02586) issued an announcement on January 30, 2026 that the company invested 3.138 million Hong Kong dollars to repurchase 374,500 shares at a repurchase price of 8.28-8.60 Hong Kong dollars per share.
DMALL (02586) announced that on January 30, 2026, the company spent 3.138 million Hong Kong dollars to repurchase 37.45 thousand shares at a repurchase price of 8.28-8.60 Hong Kong dollars per share.
Related Articles
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)
HK Stock
From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?
New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)
From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?
HK Stock
New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
RECOMMEND
Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
icon
30/01/2026
Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
icon
30/01/2026
2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
icon
30/01/2026
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.